ArticlePlant biotechnology journal2026
Generation and plant production of recombinant fluorescent immunoglobulin G as innovative immunodiagnostic reagents.
Article in Plant biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunodiagnostic systems for on-site screening are increasingly in demand but require expensive reagents such as chemically modified antibodies. To obtain biomolecules as ready-to-use reagents for diagnostics, new recombinant fluorescent immunoglobulins G were generated by fusion of the heavy chain of a monoclonal antibody, 5H3, to two different fluorescent proteins: Green Fluorescent Protein (5H3GFP) and Cyan-excitable Orange Fluorescent Protein (5H3CyOFP1). The engineered antibodies were expressed by transient agroinfiltration in Nicotiana benthamiana plants, used as bioreactor sustainable, cost-effective and easy to scale up, with a yield of 80 and 35 mg/kg of purified 5H3GFP and 5H3CyOFP1, respectively. Both recombinant proteins retained the ability to recognize the antigen of the original mAb (aflatoxin M1, a contaminant of dairy products), while simultaneously being able to emit fluorescence in the green or orange light. To demonstrate their practical application in the diagnostic field, fluorescent antibodies were exploited to set up two fast screening systems for aflatoxin M1 detection: a lateral flow immunoassay and an OLED-based device. For both diagnostic systems, antigen-specific fluorescence signals as well as a first competitive assay were obtained. Although these assays will need a further implementation, our results demonstrate a concrete possibility to develop novel and fast analytical systems based on fluorescent recombinant antibodies produced in plants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.